The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1
- PMID: 8137827
- PMCID: PMC394965
- DOI: 10.1002/j.1460-2075.1994.tb06400.x
The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1
Abstract
Human papillomavirus type 16 (HPV16) induces squamous intraepithelial lesions of the cervical mucosa which may develop into invasive cancer. The expression of viral oncogenes in advanced neoplasias appears increased relative to the proliferating cell layers of low grade lesions raising questions about molecular mechanisms of deregulation of transcription. In a lymph node metastasis of a cervical cancer, we observed full-length HPV16 plasmids and molecules with a small deletion, which was mapped to the long control region (LCR). Both wild type and shortened LCR were amplified by PCR, cloned into the promoter test plasmid pBLCAT6 and sequenced to identify a 107 bp deletion from position 7794 to 7901 in the short LCR. CAT expression in cervical cancer-derived HT3, SiHa and CaSki cells appeared 5- to 6-fold increased under the control of the short LCR. This could be traced back to elevated levels of mRNA initiated at the viral oncogene promoter. A slight further increase in CAT expression was noted in the presence of the HPV16 E2 protein which is probably due to the deletion of one E2 binding site and consequent relief from E2 repression. Computer-assisted sequence analysis and band-shift experiments with purified YY1 protein and wild type or mutated oligonucleotides identified four binding sites for this cellular transcriptional repressor within the promoter-proximal segment of the HPV16 LCR, three of which were removed by the deletion. A LCR fragment comprising these YY1 binding sites was cloned in front of the heterologous thymidine kinase gene promoter and suppressed CAT expression 3- to 4-fold.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers.Int J Cancer. 1994 Sep 15;58(6):803-8. doi: 10.1002/ijc.2910580609. Int J Cancer. 1994. PMID: 7927871
-
Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16.J Gen Virol. 1999 Aug;80 ( Pt 8):2097-2101. doi: 10.1099/0022-1317-80-8-2097. J Gen Virol. 1999. PMID: 10466808
-
Enhancer-promoter activity of human papillomavirus type 16 long control regions isolated from cell lines SiHa and CaSki and cervical cancer biopsies.Jpn J Cancer Res. 2000 Mar;91(3):271-9. doi: 10.1111/j.1349-7006.2000.tb00941.x. Jpn J Cancer Res. 2000. PMID: 10760685 Free PMC article.
-
Cellular control of human papillomavirus oncogene transcription.Mol Carcinog. 1994 Jul;10(3):134-41. doi: 10.1002/mc.2940100304. Mol Carcinog. 1994. PMID: 8043195 Review.
-
Dual Role of YY1 in HPV Life Cycle and Cervical Cancer Development.Int J Mol Sci. 2022 Mar 22;23(7):3453. doi: 10.3390/ijms23073453. Int J Mol Sci. 2022. PMID: 35408813 Free PMC article. Review.
Cited by
-
NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression.J Virol. 2004 Apr;78(8):3953-64. doi: 10.1128/jvi.78.8.3953-3964.2004. J Virol. 2004. PMID: 15047811 Free PMC article.
-
Trichostatin A up-regulates human papillomavirus type 11 upstream regulatory region-E6 promoter activity in undifferentiated primary human keratinocytes.J Virol. 1999 Jun;73(6):5026-33. doi: 10.1128/JVI.73.6.5026-5033.1999. J Virol. 1999. PMID: 10233965 Free PMC article.
-
The integration of HPV-18 DNA in cervical carcinoma.Mol Pathol. 1999 Oct;52(5):275-82. doi: 10.1136/mp.52.5.275. Mol Pathol. 1999. PMID: 10748877 Free PMC article.
-
The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element.Mol Cell Biol. 1996 Sep;16(9):4744-53. doi: 10.1128/MCB.16.9.4744. Mol Cell Biol. 1996. PMID: 8756632 Free PMC article.
-
A point mutation in the DNA-binding domain of HPV-2 E2 protein increases its DNA-binding capacity and reverses its transcriptional regulatory activity on the viral early promoter.BMC Mol Biol. 2012 Feb 15;13:5. doi: 10.1186/1471-2199-13-5. BMC Mol Biol. 2012. PMID: 22333459 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous